nach oben

Erschienen in:

08.05.2023 | Periphere arterielle Verschlusskrankheit | DDG Praxisempfehlungen

Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus

Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft für Angiologie (DGA), der Deutschen Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR) sowie der Deutschen Gesellschaft für Gefäßchirurgie und Gefäßmedizin (DGG)

verfasst von: Bernd Balletshofer, Univ.-Prof. Dr. med. Dittmar Böckler, MHBA, Holger Diener, Jörg Heckenkamp, Wulf Ito, Marcus Katoh, Dr. med. Holger Lawall, Nasser Malyar, Hui Jing Qui, Prof. Dr. med. Peter Reimer, PD Dr. med. Kilian Rittig, Markus Zähringer, DDG, DGA, DeGIR

Erschienen in: Die Diabetologie | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Auszug

Auf der Webseite der Deutschen Diabetes Gesellschaft (https://www.deutsche-diabetes-gesellschaft.de/behandlung/leitlinien) befinden sich alle PDFs zum kostenlosen Download. …

Hinchliffe RJ, Andros G, Apelqvist J (2012) A systematic review of the effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral arterial disease. Diabetes Metab Res Rev 28:179–217PubMed

Spreen MI, Martens JM, Knippenberg B et al (2017) Long-term follow-up of the PADI trial: percutaneous transluminal angioplasty versus drug-eluting stents for infrapopliteal lesions in critical limb ischemia. J Am Heart Assoc 6:e4877PubMedPubMedCentral

Lawall H, Huppert P, Rümenapf G. S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der PAVK. AWMF-LL 065/003 2015

Aboyans V, Ricco JB, Bartelink MEL et al (2018) 2017 ESC guidelines on the diagnosis and treatmenrt of peripheral arterial disease, in collaboration with the European society for vascular surgery (ESVS): document covering arterosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriey. Eur Heart J 39:763–816PubMed

Hinchliffe RJ, Forsythe R, Apelquist J et al (2019) IWGDF Guideline on diagnosis, prognosis and management of peripheral arterial disease in patients with a foot ulcer and diabetes. Diabetes Metab Res Rev 36:e3276

Fowkes GFR, Rudan D, Rudan I et al (2013) Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 382:1329–1340PubMed

Malyar N, Freisinger E, Meyborg M et al (2016) Amputations and mortality in in-hospital treated patients with peripheral arterial disease and diabetic foot syndrome. J Diabet Complicat 30:1117–1122

Cacoub PP, Bhatt DL, Steg PG et al (2009) Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 30:192–201PubMed

ASCEND Study Collaborative Group (2018) Effects of aspirin for pimary prevention in persons with diabetes mellitus. N Engl J Med 379:1529–1539

10.

McNeil JJ, Wolfe R, Woods RL et al (2018) Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Eng J Med 379:1509–1518

11.

CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329–1339

12.

EUCLID Trial Steering Committee and Investigatiors, Hiatt WR, Fowkes FG, Heizer G et al (2017) Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 376:32–40

13.

Williams B, Mancia G, Spiering W et al (2018) 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 39:3021–3104PubMed

14.

Soga Y, Iida O, Takahara M et al (2015) Beta-blocker treatment does not worsen critical limb Ischemia in patients receiving endovascular therapy. J Atheroscler Thromb 22:481–489PubMed

15.

Cosentino F, Grant PJ, Aboyans V et al (2020) 2019 ESC Guidelines on diabetes, pre-diabetes, andcardiovascular diseases developed in Colloboration with EASD. Eur Heart J 41:255–323PubMed

16.

Itoga NK, Taefik DS, Lee CK et al (2018) Association of blood pressure measurements with peripheral artery disease events. Circulation 138:1805–1814PubMedPubMedCentral

17.

Zhang W, Zaang S, Deng Y et al (2021) Trial of intensive blood-pressure control in older patients with hypertension. N Eng J Med 285:1268–1279

18.

The SPRINT Research Group (2021) Final Report of a trail of intensive versus standard bloodpressure control. Eur Heart J 384:1921–1930

19.

Anand SS, Bosch J, Eikelboom JW et al (2018) Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlles trial. Lancet 391:219–229PubMed

20.

Hsu CY, Chen YT, Su YW et al (2017) Statin therapy reduces future risk of lower-limb amputation in patients with diabetes and peripheral artery disease. J Clin Endocrinol Metab 102:2373–2381PubMed

21.

Arya S, Khakharia A, Binney ZO et al (2018) Association of statin dose with amputation and survival in patients with peripheral artery disease. Circulation 137:1435–1446PubMedPubMedCentral

22.

Momsen AH, Jensen MB, Norager CB et al (2009) Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg 38:463–474PubMed

23.

Rajamani K, Colman PG, Li LP, FIELD study investigators et al (2009) Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 373:1780–1788PubMedPubMedCentral

24.

Bonaca MP, Nault P, Giugliano RP et al (2018) Low density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation 137:338–350PubMed

25.

Khan SZ, Rivero M, Nader ND et al (2019) Metformin is associated with improved survival and decreased cardiac events with no impact on patency and limb salvage after revascularization for peripheral arterial disease. Ann Vasc Surg 55:63–77PubMed

26.

Bannister CA, Holden SE, Jenkins-Jones S et al (2014) Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls? Diabetes Obes Metab 16:1165–1173PubMed

27.

Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macrovascular events): a randomised controlled trial. Lancet 366:1279–1289PubMed

28.

Erdmann E, Dormandy JA, Massi-Benedetti M et al (2007) The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. J Am Coll Cardiol 49:1772–1780PubMed

29.

Wilcox R, Bousser MG, Betteridge DJ et al (2007) Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone clinical trial in macrovascular events04). Stroke 38:865–873PubMed

30.

Lincoff AM, Wolski K, Nicholls SJ et al (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. JAMA 298:1180–1188PubMed

31.

Kernan WN, Viscoli CM, Furie KL et al (2016) Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374:1321–1331PubMedPubMedCentral

32.

Scirica BM, Braunwald E, Raz I et al (2015) Heart failure, saxagliptin and diabetes mellitus: observations from the saVor—tiMi 53 randomized trial. Circulation 132:e198PubMed

33.

White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327–1335PubMed

34.

Zannad F, Cannon CP, Cushman WC et al (2015) Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXaMinE: a multicentre, randomised, double-blind trial. Lancet 385:2067–2076PubMed

35.

Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232–242PubMed

36.

Rosenstock J CAROLINA^®: cardiovascular safety and renal microvascular outcome with linagliptin in patients with T2D at high vascular risk. 79th Scientific Sessions of the American Diabetes Association (ADA), San Francisco, CA, USA, 10. Juni 2019 (Oral presentation)

37.

Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type2 diabetes. N Engl J Med 375:311–322PubMedPubMedCentral

38.

Marso SP, Bain SC, Consoli A, SUSTAIN‑6 Investigators et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844PubMed

39.

Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394:121–130PubMed

40.

Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128PubMed

41.

Wanner C, Inzucchi SE, Zinman B et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323–334PubMed

42.

Neal B, Perkovic V, Matthews DR (2017) Canagliflozin and cardiovascular and renal events in type2 diabetes. N Engl J Med 377:2099PubMed

43.

Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347–357PubMed

44.

Holman RR, Coleman RL, Chan JCN et al (2017) Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucosetolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 5:877–886PubMed

45.

Gerstein HC, Bosch J, Dagenais GR, ORIGIN Trial Investigators et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319–328PubMed

46.

Schaper NC, van Netten JJ, Apelqvist J et al (2020) Pracitcal Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diabetes Metab Res Rev 36(Suppl. 01):e 3266

47.

Greenhalgh RM, Belch JJ, Brown LC et al (2008) The adjuvant benefit of angioplasty in patients with mild to moderate intermittent claudication managed by supervised exercise, smoking cessation advice and best medical therapy: results from two randomised trials for stenotic femoropopliteal and aortoiliac arterial disease. Eur J Vasc Endovasc Surg 36:680–688PubMed

48.

Kersting J, Kamper L, Das M et al (2019) Leitliniengerechte Therapie der pAVK – aktuelle Studienlage und Ausblick. Fortschr Röntgenstr 191:311–322

49.

Lawall H, Huppert P, Zemmrich CS et al (2016) S3-Leitlinie PAVK – Diagnostik, Therapie und Nachsorge der peripher arteriellen Verschlusskrankheit. Vasa 45(Suppl. 95):1–100

50.

Gerhard-Hermann MD, Gornik HL, Barrett C et al (2017) 2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral artery disease: executive summary. Vasc Med 22:NP1–NP43

51.

Laird JR, Katzen BT, Scheinert D et al (2012) Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries for patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther 19:1–9PubMed

52.

Schlager O, Gschwandtner ME, Willfort-Ehringer A et al (2018) Drug coated balloons in the superficial femoral artery. J Cardiovasc Surg 59:60–69

53.

Dake MD, Ansel GM, Jaff MR et al (2016) Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5‑year results of the Zilver-PTX randomized trial. Circulation 133:1472–1483PubMedPubMedCentral

54.

Farb A, Malone M, Maisel WH et al (2021) Drug-coated devices for peripheral arterial disease. N Engl J Med 384:99–101PubMed

55.

Katsanos K, Spiliopoulos S, Kitrou P et al (2018) Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 18:1–13

56.

Empfehlung des BfArM. Empfehlung für die Verwendung von Paclitaxel-beschichteten Stents (DES) und Ballons (DCB) in der Behandlung der peripheren arteriellen Verschlusskrankheit (pAVK). Referenz Nr. 00092/19; Stand: 13. Juni 2019

57.

https://www.fda.gov/medical-devices/letters-health-care-providers/august-7-2019-update-treatment-peripheral-arterial-disease-paclitaxel-coated-balloons-and-paclitaxel

58.

Bundesinstitut für Arzneimittel und Medizinprodukte Sicherheitshinweis: Mit Paclitaxel beschichtete Ballons und Paclitaxel eluierende Stents 2020. www.bfarm.de/08249-20_kundeninfo_de

59.

Langhoff R, Behne A, Buschmann E (2018) Promising role of drug-coated balloons in the tibial vessels? J Cardiovasc Surg 57:667–676

60.

Katsanos K, Spiliopoulos S, Kitrou P et al (2020) Risk of death and amputation with use of paclitaxel-coated balloons in the infrapopliteal arteries for treatment of critical limb ischemia: a systematic review and meta-analysis of randomized controlled trials. J Vasc Interv Radiol 31:202–212PubMed

61.

Medizinischer Dienst des Spitzenverbandes Bund der Krankenkassen (MDS) Drug Eluting Balloons bei pAVK-Nutzenbewertung und Indikationskriterien (22.10.202). https://www.mds-ev.de/fileadmin/dokumente/Publikationen/GKV/Methodik/GA_DEB_pAVK_Update_201022.pdf. Zugegriffen: 1. Sept. 2021

62.

Matsuoka EK, Hasebe T, Ishii R et al (2021) Comparative performance analysis of interventional devices for the treatment of ischemic disease in below—the-knee lesions: a systematic review and meta-analysis. Cardiovasc Interv Ther 37:145–157PubMedPubMedCentral

63.

Manzi M (2018) Innovations in the management of the diabetic foot. J Cardiovasc Surg 59:653–654

64.

Walker CM (2016) Tibiopedal access for crossing of infrainguinal artery occlusions: a prospective multicenter observational study. J Endovasc Ther 23:839–846PubMed

65.

Safian RD (2017) CO2 angiography: colorless, odorless but definitely not useless. Catheter Cardiovasc Interv 90:449–450PubMed

66.

Weissler EH, Narcisse DI, Adams GL et al (2021) Characteristics and outcomes of patients with diabetes mellitus undergoing peripheral vascular intervention for Infrainguinal symptomatic peripheral artery disease. Vasc Endovascular Surg 55:124–134PubMed

67.

Bonaca MP, Bauersachs RM, Anand SS et al (2020) Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 382:1994–2004PubMed

68.

Conte MS, Bradbury AW, Kolh P. GVG Writing Group. et al (2019) Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg 69:3S–125S.e40PubMedPubMedCentral

69.

Forsythe R, Apelqvist J, Boyko EJ et al (2020) Effectiveness of revascularisation of the ulcerated foot in patients with diabetes and peripheral artery disease: A systematic review. Diabetes Metab Res Rev 36(Suppl.1):e3279PubMed

70.

Hicks C, Najafian A, Farber A et al (2016) Diabetes does not worsen outcomes following infrageniculate bypass or endovascular intervention for patients with critical limb ischemia. J Vasc Surg 64:1667–1674.e1PubMed

71.

Hock C, Betz T, Töpel I et al (2017) A comparison of tibial and peroneal venous and HePTFE bypasses in diabetics with critical limb ischemia. Surgeon 15:69–75PubMed

72.

CREDENCE Trial Investigators, Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 13:2295–2306

Titel: Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus
Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft für Angiologie (DGA), der Deutschen Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR) sowie der Deutschen Gesellschaft für Gefäßchirurgie und Gefäßmedizin (DGG)
verfasst von: Bernd Balletshofer
Univ.-Prof. Dr. med. Dittmar Böckler, MHBA
Holger Diener
Jörg Heckenkamp
Wulf Ito
Marcus Katoh
Dr. med. Holger Lawall
Nasser Malyar
Hui Jing Qui
Prof. Dr. med. Peter Reimer
PD Dr. med. Kilian Rittig
Markus Zähringer
DDG
DGA
DeGIR
Publikationsdatum: 08.05.2023
Verlag: Springer Medizin
Schlagwörter: Periphere arterielle Verschlusskrankheit
Periphere arterielle Verschlusskrankheit
Diabetes mellitus
Erschienen in: Die Diabetologie / Ausgabe 4/2023
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI: https://doi.org/10.1007/s11428-023-01043-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus

Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft für Angiologie (DGA), der Deutschen Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR) sowie der Deutschen Gesellschaft für Gefäßchirurgie und Gefäßmedizin (DGG)

Auszug

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

Interventionelle Angiologie

DDG-Praxisempfehlungen zur Ernährung von Personen mit Typ-2-Diabetes mellitus

Wirkung von Verapamil auf die Betazellfunktion des Pankreas bei neu diagnostiziertem Typ-1-Diabetes im Kindesalter

Semaglutid bei Personen mit Fettleber-assoziierter Zirrhose

DDG Praxisempfehlungen: Lipidtherapie bei Patientinnen und Patienten mit Diabetes mellitus

DDG Praxisempfehlungen: Adipositas und Diabetes

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin